Online inquiry

IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12671MR)

This product GTTS-WQ12671MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets FZD1&FZD2&FZD5&FZD7&FZD8 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_003505.2; NM_001466.4; NM_003468.4; NM_003507; NM_031866.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8321; 2535; 7855; 8324; 8325
UniProt ID Q9UP38; Q14332; Q13467; O75084; Q9H461
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ12671MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10104MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LA480
GTTS-WQ11844MR IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MK-7684
GTTS-WQ8708MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HuMax-TF-ADC
GTTS-WQ12849MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ONC-005
GTTS-WQ12776MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OMP-52M51
GTTS-WQ1155MR IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABP 215
GTTS-WQ6679MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ8094MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA h5G1.1HuG2/G4
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW